Nanexa AB - Home

VISION & MISSION

Nanexa will be a world leading drug development company for Long Acting Injectables, developing a new generation of innovative drug products enabled by our unique PharmaShell® technology”

In its state-of-the-art pilot plant and labs in Uppsala, Nanexa runs the development of own product projects and collaborative projects with other pharmaceutical companies, based on the PharmaShell® system.

PRESSRELEASES

16 April, 2024

Approval of clinical trial application for NEX-22 study delayed

Nanexa AB today announces that in the ongoing review process of the clinical trial application for the phase I study with NEX-22, additional supplements have been requested from the German Medicines Agency, which in the new European regulatory process takes more time than expected.

15 April, 2024

Notice of annual general meeting in Nanexa AB (publ)

The shareholders in Nanexa AB (publ), reg.no 556833–0285 (the ”Company”) are hereby given notice that the annual general meeting will be held on Wednesday 15 May 2024, at. 3:00 pm, at Uppsala Business Park, Rapsgatan 7, Uppsala, Sweden.